– USA, CA – Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced the appointment of Jeremy Grant to its Board as an Independent Director, bringing the Board to nine members of whom eight are independent.
“We are pleased to welcome Jeremy to the Theravance Board as a new independent director. Jeremy’s appointment underscores that Theravance values the perspectives of its investors and that the Board and management team are focused on our shared goal of maximizing value for shareholders. We look forward to benefitting from Jeremy’s financial background and perspectives as a seasoned investor,” said Chairman and CEO, Rick Winningham.
Dr. Burton Malkiel will not stand for re-election at the 2024 AGM on May 8, 2024.
About Jeremy Grant
Jeremy Grant is a Special Advisor to Irenic Capital Management LP.
Mr. Grant is the Founder and Managing Partner of Harbor Ridge LP, an investment firm, and a Special Advisor to Irenic Capital Management LP. He was previously an Associate Portfolio Manager at Elliott Management Corporation. Before Elliott, he worked as an investment professional at Oak Hill Advisors and as an analyst at Credit Suisse. Mr. Grant currently serves on the board of directors of Acosta Inc. and as an observer on the board of directors of Arconic Corporation.
“I am excited to join the Theravance Board at this time,” said Jeremy Grant. “Theravance is operating from a position of strength, and I look forward to working with my fellow directors to deliver value to shareholders.”
He is a CFA charter holder and graduated from the Wharton School at the University of Pennsylvania with a B.S. in Economics.
About Theravance Biopharma
Theravance Biopharma, Inc.’s focus is to deliver Medicines that Make a Difference in people’s lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of an FDA-approved YUPELRI inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease. Ampreloxetine, its late-stage investigational norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension, has the potential to be a first-in-class therapy effective in treating a constellation of cardinal symptoms in multiple system atrophy patients. The Company is committed to creating/driving shareholder value.
For more information: https://www.theravance.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
